DASH Plus Less Sodium: Why Both Lower Blood Pressure

Cutting sodium helps blood pressure. So does the DASH diet. The useful update is that they do not appear to do the same job twice.

Across randomized feeding studies, DASH and sodium reduction each changed blood pressure and biological markers when investigators could separate the two interventions. A broader dietary pattern rich in fruits, vegetables, whole grains, low-fat dairy, and other DASH foods appears to add something beyond sodium reduction alone. Sodium still looks like the largest single dietary lever, but treating hypertension as a salt-only problem leaves potential benefit on the table.

DASH lowers blood pressure, and lower sodium appears to add more

A systematic review and meta-analysis by Guo et al. included 10 randomized controlled trials with 2,416 adults. Participants were 45 to 62 years old, with baseline blood pressure ranging from 127–165/81–90 mmHg. Compared with control diets, the original DASH pattern reduced systolic blood pressure by about 5.5 mmHg and diastolic pressure by about 3.0 mmHg.

The review's sodium-stratified analysis found larger blood-pressure reductions when sodium targets were at or below 1,500 mg per day than when they exceeded 1,500 mg per day. The published evidence summarized here does not provide pooled subgroup estimates, so it cannot tell us exactly how many additional millimeters of mercury lower sodium delivered within each subgroup. It does support the practical conclusion that the dietary pattern and sodium target should be considered together.

The strongest design for answering that question came from DASH-Sodium: a 2×3 factorial feeding trial that crossed two dietary patterns with three sodium levels—about 1,200, 2,300, and 3,600 mg per day. That design lets researchers estimate effects of diet pattern and sodium separately instead of treating a low-sodium DASH diet as one inseparable package.

The biological signals point in different directions

In a pre-specified secondary analysis of DASH-Sodium, Juraschek et al. in 2021 examined troponin I, BNP, GDF-15, CRP, and ST2—markers related to cardiac injury, strain, and inflammation. DASH changed these biomarkers across sodium levels, while sodium reduction had its own independent trajectory. These are surrogate outcomes, not proof that either intervention prevents heart attacks or heart failure. Still, the factorial results argue that sodium restriction and the DASH pattern affect more than one shared biological switch.

A 2022 analysis of the same trial found that a low-sodium DASH pattern changed markers of inflammation and mineral metabolism in adults with elevated blood pressure. The changes correlated with blood-pressure reductions. Correlation does not establish which marker caused the pressure change, but the mineral findings fit with a plausible role for potassium and the broader sodium-to-potassium balance.

The most detailed molecular analysis came from Kim et al. in 2024. Researchers measured more than 7,000 serum proteins using SomaScan in 215 DASH participants and 390 DASH-Sodium participants, for 605 people total. They identified 71 proteins that differed between DASH and control diets. Among them were PCOLCE and CTHRC1, proteins involved in collagen remodeling.

For the DASH-Sodium comparison, researchers used the highest sodium condition—about 3,600 mg per day—as the reference. That makes the protein signature a dietary-pattern signal observed while sodium was held at the same high level, rather than a disguised sodium effect. It is intriguing evidence that DASH changes biology beyond sodium exposure.

It is not evidence that PCOLCE or CTHRC1 cause lower blood pressure. They may be downstream markers of eating the DASH pattern, or markers of adherence. No study described here shows that altering either protein changes blood pressure in people.

Sodium is still the main ingredient

A 2026 randomized trial by Duus et al. separated sodium reduction, potassium supplementation, and dietary nitrate as experimental components. It identified sodium reduction as the primary active component of dietary hypertension treatment, with potassium and nitrate making smaller independent contributions. That result corrects two common mistakes: assuming that DASH works only because it contains less sodium, and assuming that sodium no longer matters once someone eats more produce.

Potassium deserves attention because the urinary sodium-to-potassium ratio meta-analysis by Ndanuko et al. found that the ratio was more consistently associated with blood pressure than either mineral alone. A separate 2021 DASH-Sodium-derived analysis found that dietary sodium and potassium independently affected short-term blood-pressure variability. These findings support tracking the balance, not merely trying to drive sodium toward zero.

Dietary nitrate offers another plausible addition. A 2025 GRADE-assessed dose-response meta-analysis of 75 randomized trials involving 1,823 participants found that greater nitrate intake increased plasma nitrate and nitrite and was associated with dose-dependent improvements in blood pressure and vascular-health biomarkers. Each additional millimole of nitrate increased plasma nitrate by 32.7 μmol/L acutely (95% CI, 26.1 to 39.4) and 19.6 μmol/L with chronic intake (95% CI, 9.95 to 29.3). Leafy greens and beetroot fit comfortably within DASH, but the size of nitrate's blood-pressure contribution relative to sodium reduction remains uncertain because trials used different populations and nitrate delivery methods.

Does this extend beyond blood pressure?

A 2025 reanalysis of DASH-Sodium data found that sodium reduction lowered estimated 10-year ASCVD risk independently of the magnitude of blood-pressure change. An ASCVD score is a modeled risk estimate, not a count of cardiovascular events, so it should not be read as proof that sodium reduction independently prevented events during the trial. It does suggest that its effects may not be fully captured by a clinic blood-pressure reading.

The combined approach has also reached higher-risk groups. In the 2025 DASH4D randomized trial, Pilla et al. tested DASH and sodium reduction in adults with both type 2 diabetes and hypertension. Smaller trials in China tested modified DASH patterns with low-sodium salt in people with the same conditions. One eight-week trial of 132 participants reported blood-pressure reductions in all groups, with the meal-pack group decreasing by 19.06/7.82 mmHg; the study's design and multiple intervention arms mean that figure should not be treated as the isolated effect of low-sodium salt or DASH alone. The trial does, however, show that the strategy can be adapted to a high-salt food environment.

The hard part is eating this way outside a feeding trial

Controlled feeding studies can verify adherence with food records and urinary biomarkers. Ordinary life includes restaurant meals, packaged food, travel, family preferences, medication changes, and the fact that nobody wants to spend every evening calculating sodium. Guo et al. identified adherence as the main obstacle to real-world DASH effectiveness, and the trials in the review lasted only four to 48 weeks.

Medication also complicates component estimates. Diuretics, ACE inhibitors, ARBs, calcium-channel blockers, and beta-blockers can interact differently with sodium and potassium intake. Studies that include medicated participants without fully stratifying by drug class cannot precisely assign every millimeter of mercury to diet alone.

For blood-pressure management, use both levers: build meals around the DASH pattern and reduce sodium, while getting potassium from foods unless a clinician has advised otherwise because of kidney disease or medication use.

The mechanistic story is more developed than the usual "eat less salt" advice suggests. Sodium reduction remains the leading component, but DASH, potassium balance, and nitrate-rich foods appear to contribute through partly distinct pathways. The sensible goal is not to chase collagen proteins or treat a biomarker panel as a home project. It is to make the combined dietary pattern repeatable long enough for blood-pressure readings to show whether it works for you.